View ValuationGenerate Biomedicines 향후 성장Future 기준 점검 2/6Generate Biomedicines 의 수익은 연간 9% 감소할 것으로 예상되는 반면, 연간 수익은 33.5% 로 증가할 것으로 예상됩니다. EPS는 연간 10.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -55.7% 로 예상됩니다.핵심 정보-9.0%이익 성장률10.89%EPS 성장률Biotechs 이익 성장24.8%매출 성장률33.5%향후 자기자본이익률-55.68%애널리스트 커버리지Good마지막 업데이트14 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates속보 • May 22Nvidia Invests US$10.4 Million in Generate Biomedicines Advancing AI Drug ProgramsNvidia invested US$10.4 million in Generate Biomedicines, providing capital to support the company’s AI-driven generative biology platform. Generate Biomedicines is moving multiple AI-designed drug programs into clinical development, including candidates targeting severe asthma and oncology indications. The Nvidia stake highlights rising interest in AI applications within healthcare and drug discovery, with Generate Biomedicines positioned as an example of this trend. Nvidia’s backing puts a spotlight on Generate Biomedicines’ approach to using AI for drug design and gives the company added financial and reputational support as it advances into clinical testing. Investors may want to track how quickly these programs progress in the clinic and how the company manages the scientific, regulatory and capital risks that come with early-stage drug development.Reported Earnings • May 11First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$1.07 loss per share. Net loss: US$69.2m (flat on 1Q 2025). Revenue exceeded analyst estimates by 70%. Earnings per share (EPS) missed analyst estimates by 105%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.New Risk • May 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$204m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Shares are highly illiquid. Earnings are forecast to decline by an average of 9.0% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years).Recent Insider Transactions • Mar 08CEO & Director recently bought US$240k worth of stockOn the 4th of March, Michael Nally bought around 20k shares on-market at roughly US$12.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.공시 • Feb 28Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million.Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $16 Discount Per Security: $1.04 Transaction Features: Reserved Share Offering; Sponsor Backed Offering이익 및 매출 성장 예측NasdaqGS:GENB - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202892-331-236N/A412/31/202724-302-223-256612/31/202626-285-239-23363/31/202630-265-234-228N/A12/31/202532-250-204-201N/A12/31/202420-214-121-118N/A애널리스트 향후 성장 전망수입 대 저축률: GENB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: GENB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: GENB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: GENB 의 수익(연간 33.5%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: GENB 의 수익(연간 33.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GENB는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 00:51종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Generate Biomedicines, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Eric SchmidtCantor Fitzgerald & Co.Salveen RichterGoldman SachsSeamus FernandezGuggenheim Securities, LLC3명의 분석가 더 보기
속보 • May 22Nvidia Invests US$10.4 Million in Generate Biomedicines Advancing AI Drug ProgramsNvidia invested US$10.4 million in Generate Biomedicines, providing capital to support the company’s AI-driven generative biology platform. Generate Biomedicines is moving multiple AI-designed drug programs into clinical development, including candidates targeting severe asthma and oncology indications. The Nvidia stake highlights rising interest in AI applications within healthcare and drug discovery, with Generate Biomedicines positioned as an example of this trend. Nvidia’s backing puts a spotlight on Generate Biomedicines’ approach to using AI for drug design and gives the company added financial and reputational support as it advances into clinical testing. Investors may want to track how quickly these programs progress in the clinic and how the company manages the scientific, regulatory and capital risks that come with early-stage drug development.
Reported Earnings • May 11First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2026 results: US$1.07 loss per share. Net loss: US$69.2m (flat on 1Q 2025). Revenue exceeded analyst estimates by 70%. Earnings per share (EPS) missed analyst estimates by 105%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.
New Risk • May 07New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$204m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$204m free cash flow). Shares are highly illiquid. Earnings are forecast to decline by an average of 9.0% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$331m net loss in 3 years).
Recent Insider Transactions • Mar 08CEO & Director recently bought US$240k worth of stockOn the 4th of March, Michael Nally bought around 20k shares on-market at roughly US$12.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
공시 • Feb 28Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million.Generate Biomedicines, Inc. has completed an IPO in the amount of $400 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $16 Discount Per Security: $1.04 Transaction Features: Reserved Share Offering; Sponsor Backed Offering